Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is among the stocks under $50 to buy now. On January 20, TheFly reported that H.C. Wainwright lifted the price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $120 from $110 and maintained a Buy rating. The new target suggests an upside potential of 177%.

This positive outlook comes right after Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its preliminary 4Q25 and full-year 2025 financial results for its VYKAT XR offering, in which the company’s preliminary unaudited full-year 2025 net revenue surpassed the firm’s estimates by $16.5 million to $18.5 million. That said, preliminary fourth-quarter 2025 net revenue is anticipated to be between $90 and $92 million. This is substantially higher than the analyst’s guidance of $73.8 million.

On the same day, Derek Archila from Wells Fargo also increased the price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $114 from $106 and reaffirmed an Overweight rating, according to TheFly. While highlighting the fourth-quarter Vykat extended-release revenues beat, the firm believes FY26 forecasts are reasonable and notes that the shares are trading at a significant discount considering its free cash flow profile.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a California-based clinical-stage biopharmaceutical company specializing in novel therapeutics to treat serious illnesses. Founded in 1999, the company provides Diazoxide Choline Extended-Release tablets.

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.